France myocardial infarction (MI) market is estimated to grow considerably, at a CAGR of around 3.9% during the forecast period. The rise in lifestyle-oriented diseases such as CHD, CVD, stroke, and other heart diseases is creating a huge demand for cardiology surgeries in France. High consumption of alcohol, smoking, high level of animal fat consumption, serum total cholesterol, and high-density lipoprotein cholesterol concentrations are the key factors responsible for the high risk of heart attacks among the population of the country. As a result, the individual is more prone to MI and other heart diseases. Hypertension, high blood pressure, obesity, diabetes, dyslipidemia, and over-weight are the key factors that are responsible for stroke, CVD, CHD, and other heart diseases.
The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.
The companies which are contributing to the growth of France myocardial infarction market include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Novartis AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Medtronic PLC, Merck KGaA, and Sanofi SA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in April 2019, Sanofi SA announced that its product Praluent has been approved by the US FDA. Praluent intends to decrease the risk of heart attack, stroke, and unstable angina that requires the hospitalization of adults. This product approval enabled the company to broaden its product and service portfolio.
Research Methodology
The market study of the France myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. France Myocardial Infarction Market by Type
5.1.1. Non-ST-elevation myocardial infarction (NSTEMI)
5.1.2. ST-elevation myocardial infarction (STEMI)
5.1.3. Silent Heart Attacks
5.2. France Myocardial Infarction Market by Device
5.2.1. Left Ventricular Assist Device (LVAD)
5.2.2. Pacemaker
5.2.3. Catheters
5.2.4. Implantable Cardioverter-Defibrillator (ICD)
5.2.5. Others (Stent Graft)
5.3. France Myocardial Infarction Market by Diagnosis
5.3.1. Electrocardiography (ECG)
5.3.2. Chest X-Ray
5.3.3. Computed Tomography (CT Scan)
5.3.4. Echocardiography
5.3.5. Others (Blood Test)
5.4. France Myocardial Infarction Market by Treatment
5.4.1. Medication
5.4.1.1. Analgesics
5.4.1.2. Thrombolytic
5.4.1.3. Antiplatelet Agents
5.4.1.4. Glycoprotein IIb/IIIa Inhibitors
5.4.1.5. Others (Beta-Adrenergic Blockers)
5.4.2. Surgery
5.4.2.1. Angioplasty
5.4.2.2. Bypass Surgery
5.4.2.3. Heart Transplant
5.5. France Myocardial Infarction Market by End-User
5.5.1. Hospital & Clinics
5.5.2. Ambulatory Surgical Centers
5.5.3. Research Institutes
6. Company Profiles
6.1. Abbott Laboratories Inc.
6.2. AstraZeneca PLC
6.3. Bayer AG
6.4. Boehringer Ingelheim International GmbH
6.5. Boston Scientific Corp.
6.6. Bristol-Myers Squibb Co.
6.7. Eli Lilly and Co.
6.8. GlaxoSmithKline Plc
6.9. Johnson & Johnson Services, Inc.
6.10. Koninklijke Philips N.V.
6.11. Medtronic PLC
6.12. Merck KGaA
6.13. Novartis AG
6.14. Pfizer Inc.
6.15. Sanofi SA
6.16. Siemens AG
1. FRANCE MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
2. FRANCE MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICE, 2019-2026 ($ MILLION)
3. FRANCE MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2019-2026 ($ MILLION)
4. FRANCE MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
5. FRANCE MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2019-2026 ($ MILLION)
1. FRANCE MYOCARDIAL INFARCTION MARKET SHARE BY TYPE, 2019 VS 2026 (%)
2. FRANCE MYOCARDIAL INFARCTION MARKET SHARE BY DEVICE, 2019 VS 2026 (%)
3. FRANCE MYOCARDIAL INFARCTION MARKET SHARE BY DIAGNOSIS, 2019 VS 2026 (%)
4. FRANCE MYOCARDIAL INFARCTION MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
5. FRANCE MYOCARDIAL INFARCTION MARKET SHARE BY END-USERS, 2019 VS 2026 (%)